Sofinnova Partners | Sofinnova Capital XI
◆ Fund Size
$750M
◆ Check Size
◆ Location
France
◆ Portfolio
500 companies
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
Targeting early-stage medical technology and biopharmaceutical companies that seek to meet pressing unmet clinical needs through a science-driven investment approach.
◆ About Sofinnova Partners
Sofinnova Partners' Capital XI is a €650M ($750M) fund focused on early-stage biopharmaceutical and medtech companies addressing urgent unmet clinical needs in areas like oncology, inflammation, immunology, CNS, and cardio-metabolic diseases. The fund primarily invests in Series A rounds, with some seed financings, across Europe and North America, leveraging the firm's multi-strategy platform and experienced team. It emphasizes leading rounds with larger-than-median cheque sizes of around €25M to support companies long-term.
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Anta Gkelou | Partner | Senior | |
| Antoine Papiernik | Chairman & Managing Partner | Senior | |
| Graziano Seghezzi | Managing Partner | Senior | |
| Henrijette Richter | Managing Partner | Senior | |
| Karl Naegler | Partner | Senior | |
| Maina Bhaman | Partner | Senior | |
| Anne Osdoit | Deal lead | — | |
| Cedric Moreau | Partner | Partner | |
| Claire Catherinet | Senior Associate | Senior Associate | |
| Edward Kliphuis | Deal lead | — | |
| Elliott Puttock | Analyst | Analyst | |
| Guillaume Baxter | Deal lead | — | |
| Jacques Theurillat | Partner | Partner | |
| Joe Anderson | Partner | Partner | |
| Joško Bobanović | Deal lead | — | |
| Kinam Hong | Partner | Partner | |
| Lucia Faccio | Deal lead | — | |
| Mano Iyer | Deal lead | — | |
| Michael Krel | Deal lead | — | |
| Monique Saulnier | Deal lead | — | |
| Paola Pozzi | Deal lead | — | |
| Simon Turner | Deal lead | — |
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Sofinnova Capital XI invest in?
Sofinnova Capital XI invests in Biotech, Medtech, Drug Discovery, Diagnostics and Digital Health at the seed stage.
Which geographies does Sofinnova Capital XI focus on?
Sofinnova Capital XI focuses on Europe and United States, and is headquartered in France.
What is Sofinnova Capital XI's typical check size?
Sofinnova Capital XI typically writes checks of $20M to $30M.